The pharmaceutical pricing debate in Britain has been thrown into sharp relief by Canada’s recent move to approve a generic version of semaglutide, the active ingredient in blockbuster diabetes and weight-loss drug Ozempic. While the UK’s National Health Service wrestles with the cost of these increasingly popular drugs, Canada’s decision to allow a cheaper alternative highlights a glaring disparity in market dynamics and fiscal priorities.
For years, the UK has relied on a complex system of price negotiations and profit controls to manage drug expenditure. Yet the arrival of generic semaglutide in Canada, priced at roughly half the cost of the branded version, raises uncomfortable questions. Why can’t British patients access similar savings? The answer, as always, lies in the interplay of intellectual property law, market size, and political will.
Ozempic and its sister drug Wegovy have become household names, fuelled by celebrity endorsements and a growing obesity crisis. Novo Nordisk, the Danish manufacturer, has reaped enormous profits. But with patents expiring in some markets, generic manufacturers are circling. Canada’s health regulators have seized the opportunity, approving a generic version that promises to slash costs for both the government and patients. The UK’s National Institute for Health and Care Excellence (NICE), meanwhile, has been cautious, weighing the benefits against the hefty price tag.
This is not simply a story of corporate greed versus public health. The economics of drug development are brutal. The cost of bringing a new drug to market runs into billions, and patents provide the necessary incentive. But when a drug becomes a cultural phenomenon, the calculus changes. The demand for semaglutide has soared, stretching NHS budgets and exacerbating inequalities. Those who can afford private prescriptions get access; those who cannot are left waiting.
Canada’s move might be seen as a modest victory for patients, but it also exposes the fragility of the UK’s pricing model. The British government has long championed a system that balances innovation with accessibility. Yet the gap between what the NHS pays and what other countries pay is widening. A recent analysis by the King’s Fund found that the UK often pays more for branded drugs than comparable nations, despite lower overall healthcare spending.
The problem is not just semaglutide. It is a symptom of a broader malaise. The UK’s pharmaceutical market is heavily regulated, but the regulations often favour incumbent producers. Patent extensions, data exclusivity, and legal challenges delay the entry of generics. Meanwhile, the NHS is left to foot the bill. This is not sustainable. As the population ages and chronic diseases proliferate, the pressure on drug budgets will only intensify.
Some will argue that the UK should follow Canada’s lead and fast-track generic approvals. But the devil is in the details. Canada’s market is smaller, and its regulatory environment is different. Generic manufacturers may find the UK less attractive due to pricing controls that squeeze margins. Moreover, the UK’s departure from the European Union has complicated trade and regulatory alignment, potentially delaying access to cheaper drugs.
Nevertheless, the Canadian example should serve as a wake-up call. The Treasury, already strained by the cost-of-living crisis and stagnant growth, cannot afford to ignore the potential savings. Every pound spent on overpriced drugs is a pound not spent on nurses, infrastructure, or tax cuts. The Chancellor would do well to direct the Department of Health and Social Care to review the barriers to generic entry. Market efficiency demands it.
In the end, this is a classic trade-off between short-term gains and long-term innovation. You cannot artificially suppress drug prices without risking future investment. But you also cannot ignore the here and now. Patients in Britain deserve access to effective treatments at a fair price. If Canada can make it work, why can’t we? The answer lies not in the molecules, but in the market. And the market, as always, will have its say.
